Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy

Abstract

Today, vaccinologists have come to understand that the hallmark of any protective immune response is the antigen. However, it is not the whole antigen that dictates the immune response, but rather the various parts comprising the whole that are capable of influencing immunogenicity. Protein-based antigens hold particular importance within this structural approach to understanding immunity because, though different molecules can serve as antigens, only proteins are capable of inducing both cellular and humoral immunity. This fact, coupled with the versatility and customizability of proteins when considering vaccine design applications, makes protein-based vaccines (PBVs) one of today's most promising technologies for artificially inducing immunity. In this review, we follow the development of PBV technologies through time and discuss the antigen-specific receptors that are most critical to any immune response: pattern recognition receptors, B cell receptors, and T cell receptors. Knowledge of these receptors and their ligands has become exceptionally valuable in the field of vaccinology, where today it is possible to make drastic modifications to PBV structure, from primary to quaternary, in order to promote recognition of target epitopes, potentiate vaccine immunogenicity, and prevent antigen-associated complications. Additionally, these modifications have made it possible to control immune responses by modulating stability and targeting PBV to key immune cells. Consequently, careful consideration should be given to protein structure when designing PBVs in the future in order to potentiate PBV efficacy.

Immunoprotective Activity Induced by Leptospiral Outer Membrane Proteins in Hamster Model of Acute Leptospirosis

“…Lsa14 and Lsa24.9 induced exclusively IgG2/3 antibodies (Figure 3). The mechanism underlying the absence of IgG1 after immunization with these antigens is not yet clear, but it seems that the presence of IgG subclasses is dependent on several factors, including the structure of the antigen, dose, administration route, and host genetic background (27)(28)(29)(30).…”

Novel and emerging mutations of SARS-CoV-2: Biomedical implications

“…At least one of the serotypes must have a D614G mutation and associated mutations that alter the interaction of neutralizing antibodies. These mutations change immunogenicity and the structure and sequence of immunodominant linear and conformational epitopes and escape capability from humoral immune pressure, otherwise retain the strong binding affinity toward ACE2 [104] , [105] .…”

Recent Development of Ruminant Vaccine Against Viral Diseases

“…The use of cross-linking agents (e.g., formaldehyde, glutaraldehyde, aldrithiol, or 2,2 / -dithiodipyridine) for vaccine production is plagued by two primary disadvantages. The first is the possibility of aggregation, which may result in antigenic epitope disruption or alteration, potentially accounting for the vaccines' decreased immunogenicity, which typically requires two or three booster doses to maintain sufficient and long-lasting levels of protective immunity ( 106 , 107 ). Another concern is the risk of insufficient inactivation, which could lead to disease exacerbation if partially (or suboptimal) induced immunity cooperates with infectivity through pathways such as antibody-dependent enhancement (ADE) ( 108 ).…”